Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK2 | P24941 | 8/20 | 0.49 |
| ▸ | GPR34 | Q9UPC5 | 6/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | YAP1 | P46937 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3501132 | 1.00 | CDK2 (0.49) | CDK2GPR34NOS2YAP1FFAR1 | |
| SCHEMBL3497044 | 0.96 | CDK2 (0.53) | CDK2GPR34YAP1PTPN1 | |
| SCHEMBL3497042 | 0.96 | CDK2 (0.53) | CDK2GPR34YAP1PTPN1 | |
| SCHEMBL3499627 | 0.93 | CDK2 (0.50) | CDK2GPR34YAP1FFAR1PTPN1 | |
| SCHEMBL3499625 | 0.93 | CDK2 (0.50) | CDK2GPR34YAP1FFAR1PTPN1 | |
| SCHEMBL3497026 | 0.93 | GPR34 (0.53) | CDK2GPR34YAP1PTPN1 | |
| SCHEMBL3500205 | 0.93 | CDK2 (0.50) | CDK2GPR34YAP1FFAR1PTPN1 | |
| SCHEMBL3497029 | 0.93 | GPR34 (0.53) | CDK2GPR34YAP1PTPN1 | |
| SCHEMBL3500203 | 0.93 | CDK2 (0.50) | CDK2GPR34YAP1FFAR1PTPN1 | |
| SCHEMBL3497265 | 0.93 | CDK2 (0.47) | CDK2GPR34YAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-05-27 | — | — | US | disclosed |
| EP-1849465-A1 | AGENT FOR CONTROLLING FUNCTION OF GPR34 RECEPTOR | Takeda Pharmaceutical Company Limited (JP) | 2007-10-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130737-A1 | Regulating Agent of GPR34 Receptor Function | GPR34, GPR4, GPR6 | CDK2 2075/4885GPR34 1/4885NOS2 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.